Get the Stockscreener App
45.00
0.99%
0.44
After Hours:
45.00
Protagonist Therapeutics Inc stock is traded at $45.00, with a volume of 533.71K.
It is up +0.99% in the last 24 hours and up +4.92% over the past month.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
See More
Previous Close:
$44.56
Open:
$44.02
24h Volume:
533.71K
Relative Volume:
0.59
Market Cap:
$2.64B
Revenue:
$45.48M
Net Income/Loss:
$162.11M
P/E Ratio:
-16.79
EPS:
-2.68
Net Cash Flow:
$-64.16M
1W Performance:
-2.49%
1M Performance:
+4.92%
6M Performance:
+55.55%
1Y Performance:
+169.78%
1-Day Range:
$44.01
$45.38
1-Week Range:
$44.01
$47.66
52-Week Range:
$13.72
$48.00
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
How does Protagonist Therapeutics Inc (PTGX) change from a tortoise to a hare? - SETE News
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Cubist Systematic Strategies LLC - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Marshall Wace LLP - MarketBeat
Protagonist Therapeutics Inc (PTGX) did well last session? - US Post News
Point72 Asset Management L.P. Has $31.52 Million Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Dark Forest Capital Management LP Invests $2.11 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Upgraded by TD Cowen to "Strong-Buy" - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Upgraded at TD Cowen - Defense World
Dark Forest Capital Management LP Acquires Shares of 60,962 Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by Analysts at TD Cowen - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Farallon Capital Management LLC - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by TD Cowen - MarketBeat
Renaissance Technologies LLC Grows Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
TD Cowen Initiates Coverage of Protagonist Therapeutics (PTGX) with Buy Recommendation - MSN
Inspire Investing LLC Sells 2,106 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
(PTGX) Trading Signals - Stock Traders Daily
Protagonist Therapeutics sees board reshuffle, Swisher steps down - Investing.com
Protagonist Therapeutics sees board reshuffle, Swisher steps down By Investing.com - Investing.com Canada
Protagonist Therapeutics sees board reshuffle, Swisher steps down By Investing.com - Investing.com Australia
Protagonist Therapeutics Inc [NASDAQ: PTGX] Sees Increase in Stock Value - Knox Daily
Seven Eight Capital LP Has $1.28 Million Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics Board and Audit Committee Changes - TipRanks
Daily Progress: Protagonist Therapeutics Inc (PTGX) Gain 2.57, Closing at 45.92 - The Dwinnex
Seven Eight Capital LP Has $1.28 Million Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
PureCycle Technologies (NYSE:PCT) Stock Price Up 7% - MarketBeat
Why Progyny Stock Is Crashing TodayTHE BHARAT EXPRESS NEWS - The Bharat Express News
Financial Snapshot: Analyzing PTC Therapeutics Inc (PTCT)’s Key Ratio Metrics - The Dwinnex
Taking a look at what insiders are doing to gauge the PureCycle Technologies Inc (PCT)’s direction - Knox Daily
Why Progyny Stock Is Crashing Today - Yahoo Finance
Investing in PTC Therapeutics Inc (PTCT) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
A stock that deserves closer examination: Protagonist Therapeutics Inc (PTGX) - US Post News
Rhumbline Advisers Cuts Stock Position in POSCO Holdings Inc. (NYSE:PKX) - Defense World
PureCycle adjusts preferred stock rights amid investor waivers By Investing.com - Investing.com
A History of Outperforming Analyst Forecasts and Beating the Odds: PureCycle Technologies Inc (PCT) - SETE News
Market Recap: PureCycle Technologies Inc (PCT)’s Negative Momentum, Closing at 8.76 - The Dwinnex
JANE'S ADDICTION Releases New Single 'True Love' - BLABBERMOUTH.NET
The Psychology of PureCycle Technologies Inc Inc. (PCT) Price Performance: Understanding Market Sentiment - The InvestChronicle
Arizona State Retirement System Lowers Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Quest Partners LLC - Defense World
PureCycle Technologies Inc (PCT) rating reiterates by TD Cowen - Knox Daily
Analyzing PTC Therapeutics Inc (PTCT) After Recent Trading Activity - Knox Daily
Check Out PTC Therapeutics Inc (PTCT)’s Trade Data Rather Than the Analysts’ Views - SETE News
A better buy-in window may exist right now for Protagonist Therapeutics Inc (PTGX) - SETE News
Protagonist Therapeutics Inc (PTGX) Becoming More Attractive for Investors - Knox Daily
Sylebra Capital makes $20 million purchase of PureCycle Technologies stock - Investing.com
PureCycle Technologies Inc (PCT) stock analysis: A simple moving average approach - US Post News
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 52-Week High at $47.75 - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Sells $631,891.47 in Stock - Defense World
Principal Financial Group Inc. Sells 4,341 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist therapeutics CFO sells over $630k in company stock By Investing.com - Investing.com Australia
Protagonist therapeutics CFO sells over $630k in company stock - Investing.com
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):